UV-Spectrophotometric Absorbance Correction Methods for the Simultaneous Estimation of Tenofovir Alafenamide and Emtricitabine in Bulk and Tablet Dosage Form

Two UV-spectrophotometric methods have been developed and validated for simultaneous estimation of Tenofovir alafenamide (TAF) and Emtricitabine (EMT) in bulk and tablet dosage form. The Method A employs absorption correction method in zero order, the wavelengths selected were 261.5 nm for TAF (but EMT shows absorbance) and 302 nm for EMT. Method B employs, absorption correction method in first order, the wavelengths selected were 218.5 nm for TAF (but EMT shows absorbance) and 300 nm for EMT. For both the methods drugs were linear between the range of 2-10 µg/ml for TAF and 16-80 µg/ml for EMT using methanol as solvent. The correlation coefficient was found to be 0.9996 for TAF and 0.9997 for EMT for method A and 0.9998 for TAF and 0.9999 for EMT for method B, respectively. The precision (intraday, interday) of methods was found within limits (RSD < 2%). It could be concluded from the results obtained in the present investigation that the two methods for simultaneous estimation of TAF and EMT in bulk and tablet dosage form are simple, rapid, accurate, precise and economical and can be used, successfully, in the quality control of tablet formulations and other routine laboratory analysis.